# Impedimed (Australia) > company in Brisbane, Australia **Wikidata**: [Q104480726](https://www.wikidata.org/wiki/Q104480726) **Source**: https://4ort.xyz/entity/impedimed-australia ## Summary Impedimed (Australia) is a publicly traded medical technology company founded in 1999 and headquartered in Brisbane, Australia. It operates as IMPEDIMED LIMITED on the Australian Securities Exchange under ticker symbol IPD, where it has been listed since October 24, 2007, with a market capitalization of AUD 302,156,737 as of November 18, 2021. ## Key Facts - Founded in 1999 as a business entity and public company in Australia. - Official legal name is IMPEDIMED LIMITED, with "Impedimed" serving as its trading and brand name. - Listed on the Australian Securities Exchange (ASX) since October 24, 2007, with the ticker symbol IPD. - Recorded market capitalization of AUD 302,156,737 on November 18, 2021. - Maintains a corporate website at https://www.impedimed.com/. - Registered with Research Organization Registry (ROR) under ID 02x8kt557, as documented on July 6, 2021. - Assigned GRID identifier grid.509408.0 in authoritative databases. - Cataloged in Scilit with organization ID 99001. - Company logo publicly available through Wikimedia Commons at the specific URL: https://commons.wikimedia.org/wiki/Special:FilePath/ImpediMed-website-logo.png. - Geographic coordinates associated with the entity are recorded as 33.133926 latitude and -117.287564 longitude in reference databases, though the company's described location is Brisbane, Australia. ## FAQs **What is Impedimed (Australia) and how is it structured?** Impedimed (Australia) is a medical technology business that operates as a public company under the official name IMPEDIMED LIMITED. It was established in 1999 and incorporated in Australia, making its securities available to public investors through the Australian Securities Exchange. **When did Impedimed become a publicly traded company?** The company transitioned to public status on October 24, 2007, when it commenced trading on the Australian Securities Exchange with the ticker symbol IPD, following its founding in 1999 as a private entity. **What is Impedimed's market valuation and trading information?** As of November 18, 2021, Impedimed's market capitalization stood at AUD 302,156,737. The stock trades on the ASX under ticker IPD, a listing that has been active since late 2007. **Where is Impedimed located, and why do coordinates show a different location?** The company is described in its primary documentation as being based in Brisbane, Australia. However, reference databases associate it with geographic coordinates (33.133926, -117.287564) that correspond to a location in California, USA, creating a documented discrepancy between textual and geospatial records. **What authoritative identifiers are assigned to Impedimed for research and academic purposes?** Impedimed carries multiple institutional identifiers: Research Organization Registry (ROR) ID 02x8kt557, Global Research Identifier Database (GRID) entry grid.509408.0, and Scilit organization ID 99001, enabling precise citation and tracking in scholarly and financial research. ## Why It Matters Impedimed represents a significant player in Australia's publicly traded medical technology sector, demonstrating the country's capacity to nurture companies that reach public markets. Its continuous listing on the ASX since 2007 provides investors with exposure to the medical device and diagnostic technology industry, while its comprehensive set of research identifiers (ROR, GRID, SCILIT) facilitates academic study, institutional tracking, and bibliometric analysis. The company's documented market capitalization offers a concrete valuation snapshot that reflects investor confidence and market conditions in the Australian healthcare technology landscape. The existence of conflicting location data—textual references to Brisbane versus Californian coordinates—highlights the importance of data verification in corporate intelligence and research database management, serving as a case study in how entity information can vary across authoritative sources. ## Notable For - Maintaining an unbroken public listing on the Australian Securities Exchange for over 14 years since its 2007 debut. - Possessing a precise market capitalization figure of AUD 302,156,737 captured at a specific point in time (November 18, 2021), providing rare granular financial data. - Holding three distinct research identifiers simultaneously (ROR, GRID, and SCILIT), indicating recognition across multiple academic and institutional knowledge systems. - Exhibiting a documented geographic discrepancy between its described Brisbane, Australia location and coordinates pointing to California, USA in reference databases. - Operating under an all-caps official corporate name (IMPEDIMED LIMITED) while using a mixed-case brand name (Impedimed) in public-facing materials and its website. ## Body ### Corporate Identity and Legal Structure Impedimed (Australia) exists as a dual-classified entity: both a "business" and a "public company" under Australian corporate law. Its legal designation is IMPEDIMED LIMITED, rendered entirely in uppercase in official ASX documentation and corporate filings. The company trades publicly under the more accessible brand name "Impedimed," creating a distinction between its formal legal identity and its market presence. This structure allows it to raise capital from public investors while maintaining a recognizable brand identity for commercial and clinical operations. ### Stock Market Presence and Financial Metrics The company's primary market identity centers on its Australian Securities Exchange listing, initiated on October 24, 2007. The ASX assigned ticker symbol IPD serves as its unique identifier in trading systems and financial data feeds. A concrete valuation metric exists from November 18, 2021, when Impedimed's market capitalization reached AUD 302,156,737. This figure, captured from official ASX directory data, provides a specific benchmark for analyzing the company's size and investor valuation at that moment in time. The longevity of its public listing—spanning more than a decade and a half—demonstrates sustained market participation and regulatory compliance. ### Digital Footprint and Brand Assets Impedimed maintains an active web presence through its official domain, https://www.impedimed.com/. The company's visual identity is preserved in public media repositories, with its logo accessible via a dedicated Wikimedia Commons URL. This digital asset management supports brand consistency across investor relations, clinical marketing, and corporate communications. The website serves as the central hub for stakeholder engagement, product information, and regulatory disclosures required of ASX-listed entities. ### Research Infrastructure and Persistent Identifiers The company is embedded in global research infrastructure through three major identifier systems. The Research Organization Registry (ROR) records Impedimed as ID 02x8kt557, with a reference timestamp of July 6, 2021. This identifier facilitates unambiguous attribution in scholarly publications and grant reporting. Simultaneously, the Global Research Identifier Database (GRID) catalogs the entity under entry grid.509408.0, linking it to broader research ecosystem mapping. Academic literature indexing is further supported by its Scilit organization ID 99001, enabling precise tracking of the company's scientific output and collaborations across publication databases. ### Geographic and Location Data Complexity A notable data quality issue emerges in location documentation. Textual descriptions consistently place Impedimed in Brisbane, Australia, aligning with its corporate identity as an Australian public company. However, structured geographic data from reference source Q104466935 associates the entity with coordinates 33.133926 latitude and -117.287564 longitude, which resolve to Carlsbad, California. This discrepancy may reflect database entry errors, historical office locations, subsidiary registrations, or international operational facilities. The conflicting data points serve as a reminder that entity verification requires cross-referencing multiple source types—textual descriptions, geospatial data, and authoritative registrations—to achieve accurate corporate intelligence. ### Temporal Milestones and Corporate Evolution The company's timeline begins with its inception in 1999, establishing its roots in the Australian medical technology sector. Eight years of private operation followed before the pivotal 2007 transition to public markets. This 1999 founding date positions Impedimed among a cohort of turn-of-the-millennium healthcare technology firms that matured into publicly traded entities. The 2007 listing date coincides with a period of growth in the ASX's healthcare and technology sectors, suggesting strategic market timing. The availability of a 2021 market cap snapshot provides a recent financial anchor point for analyzing the company's trajectory and market position relative to its 1999 origins and 2007 public debut. ## References 1. GRID Release 2020-12-09 2. [Source](https://www2.asx.com.au/markets/trade-our-cash-market/directory) 3. ROR Data Dump 8.0 (April 2021)